Assessment of immunogenicity and efficacy of a Zika vaccine using modified vaccinia Ankara virus as carriers

Assessment of immunogenicity and efficacy of a Zika vaccine using modified vaccinia Ankara virus as carriers

Zika virus (ZIKV) is an emerging mosquito-borne flavivirus that has spread to more than 70 countries worldwide since 2015. Despite active research, there are currently no licensed vaccines or therapeutics. We have previously reported the development of various adenoviral vectored vaccine candidates...

書誌詳細
主要な著者:	López-Camacho, C, Kim, Y, Abbink, P, Larocca, R, Huiskonen, J, Barouch, D, Reyes-Sandoval, A
フォーマット:	Journal article
言語:	English
出版事項:	MDPI 2019

類似資料

Assessment of Immunogenicity and Efficacy of a Zika Vaccine Using Modified Vaccinia Ankara Virus as Carriers
著者:: César López-Camacho, 等
出版事項: (2019-11-01)

Safety and immunogenicity of DNA/modified vaccinia virus ankara malaria vaccination in African adults.
著者:: Moorthy, V, 等
出版事項: (2003)

New approaches for improving the immunogenicity of modified vaccinia virus Ankara as a recombinant vaccine vector
著者:: Alharbi, N
出版事項: (2014)

Clinical development of Modified Vaccinia virus Ankara vaccines.
著者:: Gilbert, S
出版事項: (2013)

Clinical development of Modified Vaccinia virus Ankara vaccines
著者:: Gilbert, S
出版事項: (2013)

Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans.
著者:: McConkey, S, 等
出版事項: (2003)

Safety and immunogenicity of novel recombinant BCG and modified vaccinia virus Ankara vaccines in neonate rhesus macaques.
著者:: Rosario, M, 等
出版事項: (2010)

Enhanced immunogenicity for CD8+ T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara.
著者:: Schneider, J, 等
出版事項: (1998)

Safety and immunogenicity of IMVAMUNE®, a third-generation vaccine based on the modified vaccinia Ankara (MVA) strain
著者:: L. F. Stovba, 等
出版事項: (2023-04-01)

Development of Modified Vaccinia Virus Ankara-Based Vaccines: Advantages and Applications
著者:: Olga Vladimirovna Orlova, 等
出版事項: (2022-09-01)

Low Immune Cross-Reactivity between West Nile Virus and a Zika Virus Vaccine Based on Modified Vaccinia Virus Ankara
著者:: Nereida Jiménez de Oya, 等
出版事項: (2022-03-01)

Immunogenicity and efficacy of Zika virus envelope domain III in DNA, protein, and ChAdOx1 adenoviral-vectored vaccines
著者:: López-Camacho, C, 等
出版事項: (2020)

Deletion of fifteen open reading frames from modified vaccinia virus Ankara fails to improve immunogenicity
著者:: Alharbi, N, 等
出版事項: (2015)

Deletion of Fifteen Open Reading Frames from Modified Vaccinia Virus Ankara Fails to Improve Immunogenicity.
著者:: Naif Khalaf Alharbi, 等
出版事項: (2015-01-01)

Immunogenicity and Safety of Modified Vaccinia Ankara (MVA) Vaccine—A Systematic Review and Meta-Analysis of Randomized Controlled Trials
著者:: Lior Nave, 等
出版事項: (2023-08-01)

Modified Vaccinia virus Ankara-based vaccines in the era of personalized immunotherapy of cancer
著者:: Kaïdre Bendjama, 等
出版事項: (2017-09-01)

Phase 2a safety and immunogenicity testing of DNA and recombinant modified vaccinia ankara virus vaccines expressing virus-like particles
著者:: Goepfert P, 等
出版事項: (2012-09-01)

Safety and immunogenicity of novel adenovirus type 26- and modified vaccinia Ankara-vectored Ebola vaccines: a randomized clinical trial
著者:: Milligan, I, 等
出版事項: (2016)

Immunogenicity and reactogenicity of novel adenovirus type 26 and modified vaccinia Ankara-vectored Ebola vaccines: A randomized clinical trial
著者:: Milligan, I, 等
出版事項: (2016)

Enhanced immunogenicity of CD4(+) t-cell responses and protective efficacy of a DNA-modified vaccinia virus Ankara prime-boost vaccination regimen for murine tuberculosis.
著者:: Mcshane, H, 等
出版事項: (2001)

Dendritic cells infected by recombinant modified vaccinia virus Ankara retain immunogenicity in vivo despite in vitro dysfunction.
著者:: Behboudi, S, 等
出版事項: (2004)

Immunogenicity and Efficacy of Zika Virus Envelope Domain III in DNA, Protein, and ChAdOx1 Adenoviral-Vectored Vaccines
著者:: César López-Camacho, 等
出版事項: (2020-06-01)

Reactogenicity and Immunogenicity Against MPXV of the Intradermal Administration of Modified Vaccinia Ankara Compared to the Standard Subcutaneous Route
著者:: Valentina Mazzotta, 等
出版事項: (2024-12-01)

Enhanced immunogenicity and protective efficacy against Mycobacterium tuberculosis of bacille Calmette-Guerin vaccine using mucosal administration and boosting with a recombinant modified vaccinia virus Ankara.
著者:: Goonetilleke, N, 等
出版事項: (2003)

The third generation modified vaccinia Ankara vaccine is effective in preventing the transmission of mpox
著者:: Mingwang Shen, 等
出版事項: (2024-10-01)

Ty virus-like particles, DNA vaccines and Modified Vaccinia Virus Ankara; comparisons and combinations.
著者:: Gilbert, S, 等
出版事項: (1999)

Modified Vaccinia Virus Ankara as a Viral Vector for Vaccine Candidates against Chikungunya Virus
著者:: Juan García-Arriaza, 等
出版事項: (2021-08-01)

Phase I safety and immunogenicity evaluation of MVA-CMDR, a multigenic, recombinant modified vaccinia Ankara-HIV-1 vaccine candidate.
著者:: Jeffrey R Currier, 等
出版事項: (2010-11-01)

Phase 1 safety and immunogenicity evaluation of ADMVA, a multigenic, modified vaccinia Ankara-HIV-1 B'/C candidate vaccine.
著者:: Sandhya Vasan, 等
出版事項: (2010-01-01)

Immunogenicities of intravenous and intramuscular administrations of modified vaccinia virus Ankara-based multi-CTL epitope vaccine for human immunodeficiency virus type 1 in mice.
著者:: Hanke, T, 等
出版事項: (1998)

Vaccination with a modified vaccinia virus Ankara (MVA)-vectored HIV-1 immunogen induces modest vector-specific T cell responses in human subjects.
著者:: Howles, S, 等
出版事項: (2010)

Improved Host Range Selection for Recombinant Modified Vaccinia Virus Ankara
著者:: Caroline Staib, 等
出版事項: (2003-04-01)

Elements in the Development of a Production Process for Modified Vaccinia Virus Ankara
著者:: Volker Sandig, 等
出版事項: (2013-11-01)

Next-generation mpox vaccines: efficacy of mRNA-1769 compared to modified vaccinia virus Ankara in non-human primates
著者:: Leonie Mayer, 等
出版事項: (2024-11-01)

Synthetic modified vaccinia Ankara vaccines confer cross-reactive and protective immunity against mpox virus
著者:: Flavia Chiuppesi, 等
出版事項: (2024-02-01)

The Efficacy of Disinfection on Modified Vaccinia Ankara and African Swine Fever Virus in Various Forest Soil Types
著者:: Franziska Tanneberger, 等
出版事項: (2021-10-01)

Ebola virus – prospects for a novel virus-like-particle-expressing modified vaccinia Ankara-based vaccine
著者:: Harriet L. Robinson, 等
出版事項: (2018-09-01)

Expanding the repertoire of Modified Vaccinia Ankara-based vaccine vectors via genetic complementation strategies.
著者:: David A Garber, 等
出版事項: (2009-01-01)

Correction: Next-generation mpox vaccines: efficacy of mRNA-1769 compared to modified vaccinia virus Ankara in non-human primates
著者:: Leonie Mayer, 等
出版事項: (2024-12-01)

Transient Host Range Selection for Genetic Engineering of Modified Vaccinia Virus Ankara
著者:: C. Staib, 等
出版事項: (2000-06-01)